Liposomal amphotericin B associated with severe hyperphosphatemia

Pediatric Infectious Disease Journal

Volumn 27, Issue 1, 2008, Pages 77-79

  Sutherland, Scott M ^a,b   Hong, David K ^a   Balagtas, Jay ^a   Gutierrez, Kathleen ^a   Dvorak, Christopher C ^a   Sarwal, Minnie ^a  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amphotericin B; Antifungal; Hyperphosphatemia; Invasive fungal infection

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CEFTAZIDIME; PHOSPHATE; SEVELAMER; VANCOMYCIN; VORICONAZOLE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; ASPERGILLOSIS; BRAIN BIOPSY; CASE REPORT; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HUMAN; HYPERPHOSPHATEMIA; IMMUNOCOMPROMISED PATIENT; LIVER BIOPSY; MALE; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 37549009949     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/INF.0b013e31815922a3     Document Type: Article

References (11)

1. Rosen GP, Nielsen K, Glenn S, Abelson J, Deville J, Moore TB. Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution. J Pediatr Hemat Oncol. 2005;27:135-140.
2. Chen HS, Tsai WP, Leu HS, Ho HH, Liou LB. Invasive fungal infection in systemic lupus erythematosus: an analysis of 15 cases and a literature review. Rheumatology (Oxford). 2007;46:539-544.
3. Wazny LD, Brophy DF. Amiloride for the prevention of amphotericin B-induced hypokalemia and hypomagnesemia. Ann Pharmacother. 2000;34:94-97.
4. Alfrey AC. The role of abnormal phosphorus metabolism in the progression of chronic kidney disease and metastatic calcification. Kidney Int Suppl. 2004:S13-S17.
5. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7-14.
6. Fukuda T, Boeckh M, Guthrie KA, et al. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant. 2004;10:494-503.
7. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis. 1996;22(suppl 2):S133-S144.
8. Jain A, Butani L. Severe hyperphosphatemia resulting from high-dose liposomal amphotericin in a child with leukemia. J Pediatr Hematol Oncol. 2003;25:324-326.
9. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44:1289-1297.
10. Lane JW, Rehak, NN, Krause PR, Hortin GL, Walsh TJ. Pseudohyperphosphatemia Associated with Liposomal Amphotericin B. Interscience Conference on Antimicrobial Agents and Chemotherapy (Presentation M-303, Poster 490). San Francisco, CA; 2006.
11. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis. 2000;31:1155-1163.